Weiss Law investigates IMARA Inc.

NEW YORK, October 14, 2022 /PRNewswire/ — Weiss’ law investigation of possible breaches of fiduciary duty and other violations of law by the board of directors of IMARA Inc. (“IMARA” or the “Company”) (NASDAQ: IMRA) in connection with the project of the Company’s merger with Enliven Therapeutics, Inc. (“Animate”). Under the terms of the merger agreement, IMARA will issue IMARA common stock as consideration for the merger in exchange for the cancellation of shares of Enliven’s capital stock and Enliven will become a wholly owned subsidiary of IMARA. Upon completion of the transaction, IMARA shareholders are expected to own only approximately 16% of the combined company, while Enliven shareholders are expected to own approximately 84% of the combined company.

If you own IMARA actions and wish to discuss this survey or have questions about this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/imra
Or please contact:
Joshua Rubin, Esq.
Weiss’ law
305 Broadway, 7e Floor
New YorkNY 10007
(212) 682-3025
(888) 593-4771
[email protected]

Weiss Law is investigating whether (i) IMARA’s board of directors acted in the best interests of the company’s shareholders in agreeing to the proposed transaction, (ii) the minority stake in the combined company under the transaction proposed is fair to IMARA shareholders, and (iii) all information regarding the sale process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of shareholder class and derivative actions for breach of corporate and fiduciary duties. We’ve recovered more than $1 billion for defrauded customers and won significant corporate governance relief in many of those cases. If you have information or want legal advice regarding possible corporate wrongdoing (including insider trading, waste of company assets, accounting fraud or misleading information), fraud consumer rights (including false advertising, defective products or other deceptive marketing practices), or anti-trust violations, please email us at [email protected]

SOURCE Weiss’ Law

Comments are closed.